We are live on ! Find out more

LNAI

Lunai Bioworks

LNAI

Market cap $10.7M

2.37 USD

+0.02

0.85%

At close Updated Aug 28, 4:00 PM EDT

1 day

0.85%

5 days

9.72%

1 month

5.8%

3 months

-22.04%

6 months

-22.55%

Year to date

-69.5%

1 year

-88.31%

5 years

-99.61%

10 years

-99.65%

About: Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Employees: 29

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering. SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO Statute WILMINGTON, Del. and SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology.

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development SACRAMENTO, Calif. and SAN DIEGO, May 28, 2026 /PRNewswire/ -- Lunai Bioworks' (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases.

Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock

WASHINGTON, May 22, 2026 /PRNewswire/ -- On Wednesday, May 20, 2026, a United States District Court Magistrate Judge in Delaware granted the Motion of Lunai Bioworks, Inc. (Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "John Doe" "naked" short sellers of Lunai common stock on the Nasdaq Stock Market in late 2025 and throughout the first half of 2026. Co-lead counsel, Jacob Frenkel, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from the 'naked' short sellers who have caused real market harm to Lunai and its shareholders.

Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

SACRAMENTO, Calif., May 20, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI) (the "Company") today announced that it will effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share (the "Common Stock"), at a ratio of 1-for-8 (the "Reverse Stock Split").

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock

WASHINGTON, D.C. , May 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- On Monday, May 11, 2026, national law firms Dickinson Wright and Fox Rothschild joined forces to file a lawsuit on behalf of their firms' client, Lunai Bioworks, Inc. (Nasdaq: LNAI) (Lunai), alleging securities fraud (stock manipulation) and intentional tort against “John Doe” “naked” short sellers of Lunai common stock on the Nasdaq Stock Market. The Complaint alleges that the short sellers engaged in the unlawful practice of “naked short selling” in a coordinated and systematic scheme to cause substantial harm to the company and its shareholders – highlighting deceptive devices they employed to violate federal laws and regulations and avoid detection by regulators. The lawsuit, filed in federal court in Delaware, seeks unspecified compensatory and special damages and other relief.

Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applications SACRAMENTO, Calif., May 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced the completion of a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the Company's central nervous system (CNS) platform with complementary neurotherapeutic compounds and delivery technologies.

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Collaboration converts patient-led data into trial-ready cohorts to support drug development, commercial partnerships, and revenue-generating opportunities. Initial programs underway to integrate rare disease datasets and advance commercial partnership opportunities with pharmaceutical companies.

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

See News Rankings

Price charts implemented using Lightweight Charts™